These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 3119151

  • 1. Characterization of dopaminergic influence on striatal-nigral neurotensin systems.
    Letter AA, Matsuda LA, Merchant KM, Gibb JW, Hanson GR.
    Brain Res; 1987 Sep 29; 422(1):200-3. PubMed ID: 3119151
    [Abstract] [Full Text] [Related]

  • 2. Dopamine-mediated changes in central nervous system neurotensin systems: a role for NMDA receptors.
    Singh NA, Bush LG, Gibb JW, Hanson GR.
    Eur J Pharmacol; 1990 Oct 23; 187(3):337-44. PubMed ID: 2150044
    [Abstract] [Full Text] [Related]

  • 3. Neurotensin-dopamine interactions in the substantia nigra of the rat brain.
    Merchant KM, Bush LG, Gibb JW, Hanson GR.
    J Pharmacol Exp Ther; 1990 Nov 23; 255(2):775-80. PubMed ID: 2147039
    [Abstract] [Full Text] [Related]

  • 4. Response of extrapyramidal and limbic neuropeptides to fenfluramine administration: comparison with methamphetamine.
    Hanson GR, Singh N, Bush L, Gibb JW.
    J Pharmacol Exp Ther; 1991 Dec 23; 259(3):1197-202. PubMed ID: 1722253
    [Abstract] [Full Text] [Related]

  • 5. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems.
    Singh NA, Bush LG, Gibb JW, Hanson GR.
    Brain Res; 1992 Feb 07; 571(2):260-4. PubMed ID: 1351780
    [Abstract] [Full Text] [Related]

  • 6. Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density.
    Masuo Y, Pélaprat D, Montagne MN, Scherman D, Rostène W.
    Brain Res; 1990 Mar 05; 510(2):203-10. PubMed ID: 1970504
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons.
    Kerkerian L, Salin P, Nieoullon A.
    Neuroscience; 1988 Sep 05; 26(3):809-17. PubMed ID: 3143926
    [Abstract] [Full Text] [Related]

  • 8. Differential dopaminergic regulation of the neurotensin striatonigral and striatopallidal pathways in the rat.
    Castel MN, Morino P, Nylander I, Terenius L, Hökfelt T.
    Eur J Pharmacol; 1994 Sep 01; 262(1-2):1-10. PubMed ID: 7813560
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation.
    Magnusson O, Mohringe B, Fowler CJ.
    J Neural Transm; 1987 Sep 01; 69(3-4):163-77. PubMed ID: 2957465
    [Abstract] [Full Text] [Related]

  • 10. Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation.
    Sonsalla PK, Gibb JW, Hanson GR.
    Eur J Pharmacol; 1984 Oct 01; 105(1-2):185-7. PubMed ID: 6208043
    [Abstract] [Full Text] [Related]

  • 11. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Oct 01; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 12. Selective antagonists of dopamine receptor subtypes differentially affect substance P levels in the striatum and substantia nigra.
    Oblin A, Zivkovic B, Bartholini G.
    Brain Res; 1987 Sep 22; 421(1-2):387-90. PubMed ID: 2446703
    [Abstract] [Full Text] [Related]

  • 13. Nigrostriatal dopamine actions on the D2 receptors mediate methamphetamine effects on the striatonigral substance P system.
    Sonsalla PK, Gibb JW, Hanson GR.
    Neuropharmacology; 1986 Nov 22; 25(11):1221-30. PubMed ID: 2432440
    [Abstract] [Full Text] [Related]

  • 14. Neurotensin regulation of endogenous acetylcholine release from rat striatal slices is independent of dopaminergic tone.
    Lapchak PA, Araujo DM, Quirion R, Beaudet A.
    J Neurochem; 1991 Feb 22; 56(2):651-7. PubMed ID: 1899109
    [Abstract] [Full Text] [Related]

  • 15. Characterization of methamphetamine effects on the striatal-nigral dynorphin system.
    Hanson GR, Merchant KM, Letter AA, Bush L, Gibb JW.
    Eur J Pharmacol; 1988 Oct 11; 155(1-2):11-8. PubMed ID: 2907484
    [Abstract] [Full Text] [Related]

  • 16. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Mela F, Marti M, Bido S, Cenci MA, Morari M.
    Neurobiol Dis; 2012 Jan 11; 45(1):573-82. PubMed ID: 22001605
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.